Liver & Intestine Transplant Perspective

  • Sirolimus to Prevent Vasculopathy after Heart Transplant   Dr Sudhir Kushwaha describes vasculopathy following heart transplants and gives the lowdown on sirolimus-based immunosuppression.
  • Unsafe at Any Lunch? In the wake of several high-profile foodborne disease outbreaks, Dr William Balistreri details the clinical consequences, possible causes, and what can be done to stop them in the future.
  • Understanding Acute-on-Chronic Liver Failure A condition with a variety of classifications, associated complications, and manifestations, acute-on-chronic liver failure requires early identification to lessen the risk for patient mortality.
  • The Increasing Pace of Progress in Hepatology From obesity-related issues in children to the emerging role of the microbiome in multiple disorders, highlights from this year's Digestive Disease Week were as expansive as they were illuminating.
  • Screening for Hepatocellular Carcinoma Learn the risk factors for hepatocellular carcinoma, and who to screen, how often to screen, and what tools should be used.
  • Liver Diseases in Children: Challenges and Opportunities What progress has been made in the treatment of some of the most frequent liver diseases in children, and what does the future hold?
  • HCV Treatment: What Can I Do Now? What's Coming Next? As direct-acting antivirals continue to show success in HCV, the possibility for treatment expands to an even greater number of patient groups.
  • Infections in Transplant Recipients: An Overview Anyone might encounter a patient with a transplant-related infection. Shmuel Shoham explains how to evaluate for this complication of solid-organ transplantation.
  • GI Practice Updates for Primary Care Providers   Dr David Johnson makes a plea for primary care providers to team up with gastroenterologists in the prevention and management of common GI disorders.
  • Hepatitis C: 25 Years Old, and Fading A wave of new antiviral drugs and novel treatment strategies are heralding a future in which hepatitis C may be globally eradicated -- but some obstacles still remain.
  • Could It Be... E?   Elevated liver enzymes and a hepatitis A-like prodrome -- is it time to consider hepatitis E? Dr David Johnson reviews what we know.
  • Hepatitis C: Weighing the Price of a Cure A new class of drugs has proven to be an exceptional clinical success, but it's their equally striking costs that are garnering more attention.
  • No Return Trips: Hospitals Under Pressure to Lower Readmissions The pressure is on to slow down the revolving door and prevent patients from bouncing right back in after discharge.
  • Hepatitis C: Updated Guidelines and New Drugs The latest drugs to be approved for the treatment of hepatitis C virus infection are setting new standards of practice.
  • The Challenges Surrounding Primary Sclerosing Cholangitis In navigating issues such as differential diagnoses and a confounding lack of clear treatment options, clinicians are best suited by following the most recent guidelines in this area.
  • HBV: React Before the Virus Does This once-fatal condition can now be easily prevented, but to screen patients appropriately requires a level of awareness that is lacking at present.
  • Finding the Patient With Primary Biliary Cirrhosis If you don't consider it, you might miss the diagnosis of this slowly progressive autoimmune disorder.
  • Liver Disease From Alpha-1-Antitrypsin Deficiency What therapeutic options for liver failure in patients with alpha-1-antitrypsin deficiency are in the pipeline?
  • Top Highlights in Hepatology: The Liver Meeting 2014 It is an exciting time for hepatology; research presented at this year's meeting promises to alter clinical practice.
  • Advances in GI Cancer: 2014 Four experts from the Ruesch Center for the Cure of Gastrointestinal Cancers highlight progress made in gastrointestinal cancer in 2014.
avanafil online

читать дальше